65,437 trials
Insomnia
Primary: Program Engagement: Completion of the First Program Module — 17; 12; 16 Participants
Mild Dehydration
Primary: Blood Pressure Variability — 2.6; 2.5 mmHg
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
HIV Infections
Primary: Rates of HIV Seroconversion — 17; 33 Infections/ 100 person-years
COVID-19
Primary: Gender Distribution of the Patients — 19; 21; 11; 9 Participants
Diabetes Mellitus, Type 1
Primary: Treatment Emergent Antibody Response (TEAR) — 59; 67 Participants
Bradyarrhythmia
Primary: Evaluation for Equivalence of the Number of Patients Who Meet the Composite Safety Endpoint Between Home Monitoring Group(HM) and Control Group Which is HM +…
Severe Alzheimer Disease
Primary: Frequency of Treatment-emergent Adverse Events (Safety) — 8; 3 Participants
Shigellosis
Primary: Attack Rate of Shigellosis in Vaccinated Subjects. — 13; 18 Participants
Alcohol Use Disorder · Alcohol Dependence
Primary: Evaluate Safety of a Single 15 mg Dose of Rapamycin (Sirolimus) at First Visit. — 0; 3 Participants
Psoriatic Arthritis · Axial Spondyloarthritis · Enthesitis
Primary: Number (%) of Patients With Resolution of Achilles Tendon Enthesitis — 43; 32 Participants — p=0.136
Dry Eye Syndrome
Primary: A Measurable Difference in Tear Lipid Layer Thickness After 4 Weeks of Daily Use — -5.1; -3.2 nm — p=0.65
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52 — 67.4; 61.5 Percentage of Participants — p=0.0719
Diabetic Kidney Disease
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509 — 3316.1; 3266.7; 2962.1; 2835.3 hr*ng/mL
Parenteral Nutrition Associated Cholestasis
Primary: Normalization of Conjugated Bilirubin (Conjugated Bilirubin < 2 mg/dL) — 2 mg/dl